According to my path report Mayo Clinic states: The therapeutic and prognostic implications of MGMT promoter methylation status have best been studied in Glioblastoma. The presence of MGMT promoter predicts response to alkylating chemotherapy (i.e. temozolomide) and is a FAVORABLE (emphasis is mine) prognostic factor got patients with glioblastoma. Additional studies are needed to assess the clinical significance of the presence the presence of MGMT promoter methylation in other tumor types.

My own neuro-oncologist has told me several times that that the presence of MGMT promoter methylation is a good thing for me to have.
I just completed my 6 weeks of rad/temozolomide and am in my medication vacation. I had few side effects-primarily a bit of fatigue. I’m now celebrating at the beach! I will be discussing using the Optune device along with 6 more rounds of temozolomide.